Serum creatine as a biomarker for spinal muscular atrophy progression

Takeaway

  • The severity of spinal muscular atrophy (SMA) is associated with serum creatine (Crn) levels; thus, Crn could be used as a biomarker for disease progression in SMA.

Why this matters

  • Simple biomarkers that can monitor SMA disease onset, progression and treatment response are currently lacking.

  • In the future, the measurement of Crn should be part of routine analysis and monitoring of people with SMA.

Want to read more?

Log in or sign up to access all Neurodiem content.

Already have an account? Log In

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.